{"id":"e8e29dcd-56e5-590d-bd72-4d1dd21f9503","stable_key":"792249b7-a38d-5f43-afb6-2936818a3fa2:tartrazine-aspirin-asthma","predicate":"elicits_rare_challenge_response","statement":"Four of 156 aspirin-intolerant asthmatics had a double-blind-confirmed tartrazine response with more than a 25% FEV1 fall and symptoms.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"f9bdf688-8940-5f42-b090-df96a2972f30","mechanism_event_label":"Four of 156 aspirin-intolerant asthmatics had a double-blind-confirmed tartrazine response with more than a 25% FEV1 fall and symptoms.","subject":{"id":"135b5f4d-0c59-5359-a645-39796e820d42","slug":"tartrazine","display_name":"Tartrazine","entity_type_key":"small_molecule"},"object":{"id":"b518695c-261b-5f91-9e32-2f27eada6d63","slug":"human-aspirin-asthma-tartrazine-challenge","display_name":"Airway response to tartrazine in aspirin-intolerant asthmatics","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"f9bdf688-8940-5f42-b090-df96a2972f30","stable_key":"792249b7-a38d-5f43-afb6-2936818a3fa2:tartrazine-aspirin-asthma-event","event_type":"observed_relationship","label":"Four of 156 aspirin-intolerant asthmatics had a double-blind-confirmed tartrazine response with more than a 25% FEV1 fall and symptoms.","description":"Four of 156 aspirin-intolerant asthmatics had a double-blind-confirmed tartrazine response with more than a 25% FEV1 fall and symptoms.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"135b5f4d-0c59-5359-a645-39796e820d42","slug":"tartrazine","display_name":"Tartrazine","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"b518695c-261b-5f91-9e32-2f27eada6d63","slug":"human-aspirin-asthma-tartrazine-challenge","display_name":"Airway response to tartrazine in aspirin-intolerant asthmatics","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"8ac405bf-3ea0-539a-8e5e-abf503dc7081","slug":"aspirin","display_name":"Aspirin / acetylsalicylic acid","entity_type_key":"drug"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"dose","value_text":"Increasing tartrazine doses up to 25 mg; positive open challenges repeated double blind","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"duration","value_text":"Acute challenge; exact observation window not specified in abstract","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_access","value_text":"Primary PubMed abstract; unrecovered method details explicitly retained.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_scope","value_text":"literature_reviewed; source-specific experimental curation","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"156 patients with confirmed aspirin-induced asthma in a multicenter study","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Four confirmed reactions do not establish universal aspirin-tartrazine cross-reactivity or a shared IgE/COX mechanism. Results are specific to the recruited population.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Tartrazine food-colorant chapter; nutrient, drug and peptide interactions retain their models and limits.","comparator":null,"unit":null,"notes":"","entity":{"slug":"tartrazine","display_name":"Tartrazine","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"156 patients with confirmed aspirin-induced asthma in a multicenter study","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Four of 156 aspirin-intolerant asthmatics had a double-blind-confirmed tartrazine response with more than a 25% FEV1 fall and symptoms.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Intolerance to tartrazine in aspirin-induced asthma: results of a multicenter study. (1988). https://pubmed.ncbi.nlm.nih.gov/3387687/ DOI: 10.1159/000195391","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"route","value_text":"Oral tartrazine; aspirin intolerance was a selection criterion, not co-administration","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue","value_text":"Oral challenge, spirometry and symptoms","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"0db1989e-bcb1-5775-bb18-2f13ce8f5104","evidence_kind":"source_excerpt","locator":"Lines 325-334","start_line":325,"end_line":334,"excerpt":"## tartrazine-aspirin-asthma\nFour of 156 aspirin-intolerant asthmatics had a double-blind-confirmed tartrazine response with more than a 25% FEV1 fall and symptoms.\nModel/species: 156 patients with confirmed aspirin-induced asthma in a multicenter study\nTissue: Oral challenge, spirometry and symptoms\nExposure: Increasing tartrazine doses up to 25 mg; positive open challenges repeated double blind\nRoute: Oral tartrazine; aspirin intolerance was a selection criterion, not co-administration\nDuration: Acute challenge; exact observation window not specified in abstract\nLimits: Four confirmed reactions do not establish universal aspirin-tartrazine cross-reactivity or a shared IgE/COX mechanism. Results are specific to the recruited population.\nPrimary reference: Intolerance to tartrazine in aspirin-induced asthma: results of a multicenter study. (1988). https://pubmed.ncbi.nlm.nih.gov/3387687/ DOI: 10.1159/000195391\nAccess: Primary PubMed abstract; unrecovered method details explicitly retained.","model_system":"156 patients with confirmed aspirin-induced asthma in a multicenter study","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Exact original curation span, not a publisher quotation; primary citation retained.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"d9540941-68b4-5a0d-a5c1-828665a918e2","stable_key":"import-792249b7-a38d-5f43-afb6-2936818a3fa2","title":"Tartrazine: mechanisms, molecular forms and cross-actor connections (2026-09-20)","document_type":"imported_text","citation_label":"Original AI-assisted curation of eighteen primary studies. Study-specific citations, negative findings and limitations retained. Not publisher full text.","file_path":"","sha256":"b83a0113a4b743adc91c24504e488f47e10665386b299c4cb0543da8948f4246","revision_id":"3769070e-6af4-5b02-9d8e-f23c84edba1b","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}